CIGNA Member Correction

CIGNA members: Please note that you may receive a letter in the mail stating that The Dermatology Center of Indiana is no longer in your network. This communication from CIGNA is incorrect and we would like to reassure you that we are still in network with CIGNA. We look forward to continuing to service you and your family for all your dermatology needs.

2018

Moderate to Severe Facial Papulopustular Rosacea
Sponsor: Foamix
An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)
Phase: 3
Start Date: 2018
End Date: 2019

Moderate to Severe Palmar Hyperhidrosis
Sponsor: Atacama
A Double-Blind, Randomized, Placebo-Controlled Exploratory Study To Assess The Efficacy And Safety Of Tc-5214 In The Treatment Of Subjects With Moderate To Severe Palmar Hyperhidrosis
Phase: 2a
Start Date: 2018
End Date: 2018

Mildly Atopic, Chronis Rhinosinusitius with Nasal Polyps, Moderate to Severe Atopic Dermatitus
Sponsor: Pfizer
A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynmics of Single and/or Multiple Intravenous and/or Subcutaneous Doses of PF-06817024 in Healthy Subjects Who May Be Mildly Atopic, Subjects with Chronis Rhinosinusitius with Nasal Polyps, and Subjects With Moderatesevere Atopic Dermatitius
Phase:1
Start Date: 2018
End Date: 2018

Moderate to Severe Plaque Psoriasis
Sponsor: Abbvie
Clinical Study Protocol M15-997: A multicenter, open Label study to assess the safety and efficacy of rIsankizuMab for MaInTenance in moderate to severe pLaquE type pSoriaSis (LIMMITLESS)
Phase: 3
Start Date: 02/2017
End Date: Ongoing

Scalp Psoriasis
Sponsor: Celgene
A Phase 3, Multi-Center, Randomized,Placebo-Controlled, Double-Blind Study Of The Efficacy And Safety Of Apremilast (Cc-10004) In Subjects With Moderate To Severe Plaque Psoriasis Of The Scalp
Phase: 3
Start Date: 08/2017
End Date: Ongoing

Actinic Keratosis
Sponsor: Athenex
A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp
Phase: 3
Start Date: 11/2017
End Date: Ongoing

Atopic Dermatitis
Sponsor: Regeneron
An Open-Label Extension Study To Assess The Long-Term Safety And Efficacy Of Dupilumab In Patients Greater Than Or Equal To 6 Months To Less Than 18 Years Of Age With Atopic Dermatitis 6 months to less than 18 years
Phase: 3
Start Date: 02/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Dermira
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Phase: 2b
Start Date: 02/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Incyto
An Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With
Atopic Dermatitis
Less than 18 years
Phase: 1
Start Date: 04/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Leo Pharma
Tralokinumab in combination with topical corticosteroids for moderate-to-severe atopic dermatitis
ECZTRA 3 (ECZema TRAlokinumab trial no. 3)
Phase: 3
Start Date: 04/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Glenmark
A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study Of Gbr 830 In Adult Subjects
With Moderate To Severe Atopic Dermatitis
Phase: 2b
Start Date: 05/2018
End Date: 2019

Chronic Plaque Psoriasis
Sponsor: UCB
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Bimekizumab In Adult Subjects With
Moderate To Severe Chronic Plaque Psoriasis
Phase: 3
Start Date: 05/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Asana
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study To Evaluate The Efficacy, Safety,
Tolerability, And Pharmacokinetics Of Asn002 In Subjects With Moderate To Severe Atopic Dermatitis
Phase: 2b
Start Date: 06/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Lilly
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
Phase: 3
Start Date: 06/2018
End Date: Ongoing

Actinic Keratosis
Sponsor: Vidac
A Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102
Ointment in Subjects with Actinic Keratosis
Phase: 2b
Start Date: 06/2018
End Date: Ongoing

Plaque Psoriasis
Sponsor: Lilly
A Multicenter, Randomized, Double-Blind, Placebo- Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
Phase: 3
Start Date: 08/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Vanda
A Randomized, Double-Blind, Placebo Controlled, Efficacy Study Of The Neurokinin-1 Receptor
Antagonist Vly-686 In Patients With Atopic Dermatitis
Phase: 3
Start Date: 08/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Regeneron
A Prospective Observational Study Of Adult Patients Receiving Dupixent For Atopic Dermatitis
Phase: 4
Start Date: 08/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Pfizer
A Phase 3 Randomized Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating
The Efficacy And Safety Of Pf-04965842 In Subjects Aged 12 Years And Over, With Moderate To Severe
Atopic Dermatitis With The Option Of Rescue Treatment In Flaring Subjects
12 years and over
Phase: 3
Start Date: 08/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Pfizer
A Phase 3 Randomized, Double-Blind, Multi-Center, Long-Term Extension Study Investigating The
Efficacy And Safety Of Pf-04965842, With Or Without Topical Medications, Administered To Subjects
Aged 12 Years And Older With Moderate To Severe Atopic Dermatitis
12 years and older
Phase: 3
Start Date: 08/2018
End Date: Ongoing

Hidradenitis Suppurativa
Sponsor: Janssen
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to
Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa
Phase: 2
Start Date: 09/2018
End Date: Ongoing

Acne Vulgaris
Sponsor: Gagw
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in
Subjects with Acne Vulgaris.
Phase:
Start Date: 10/2018
End Date: Ongoing

Plaque Psoriasis
Sponsor: Bristol Myers- Squibb
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to
Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
Phase: 3
Start Date: 10/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Lilly
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult
Patients with Moderate to Severe Atopic Dermatitis.
Phase: 3
Start Date: 10/2018
End Date: Ongoing

Plaque Psoriasis
Sponsor: Lilly
A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment
Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis.
Phase: 3
Start Date: 10/2018
End Date: Ongoing

Plaque Psoriasis
Sponsor: Therapeutics
A Double-Blind, Randomized, Multicenter, Vehicle Controlled, Parallel Group Comparison Study to
Determine the Efficacy and Safety of Halobetasol Propionate Spray, 0.05% Versus Vehicle Spray in
Subjects with Plaque Psoriasis Receiving Up to Four Weeks of Twice Daily Treatment
Phase: 3
Start Date: 11/2018
End Date: Ongoing

Atopic Dermatitis
Sponsor: Sanofi
Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable.
Less than 18 years
Phase: 4
Start Date: 11/2018
End Date: Ongoing

Common Warts
Sponsor: Verrica
A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects with Common Warts (Verruca Vulgaris)
Phase: 2
Start Date: 12/2018
End Date: Ongoing